Specialized pro-resolving mediators (SPM Active)
What studies of Specialized pro-resolving mediators (SPM Active) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, the randomised trial and studies with no comparison group and the placebo trial (very low certainty): 3 of 6 findings are C, a tie, so the grade of daily functioning, as the rule below says.
5 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Specialized pro-resolving mediators (SPM Active) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Specialized pro-resolving mediators (SPM Active) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Fatigue2 studies · 192 people took Specialized pro-resolving mediators (SPM Active) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 53 people found no clear difference; a small benefit can't be ruled out.
The randomised trial53 randomised · 12 weeks · 3000 mg/day
No clear difference in fatigue.
The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on fatigue in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 53 people found no clear difference; a small benefit can't be ruled out
Studies with no comparison group144 randomised · after 12 weeks
Fatigue improved.
The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on fatigue in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 2 studies
-
- People in the study
- 53 randomised
- Dose
- 3000 mg/day
- Outcome
- Fatigue Severity Scale (FSS) score: differences among the four treatment groups Fatigue Severity Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
-
- People in the study
- 144 randomised
- Dose
- —
- Outcome
- fatigue (FSS) Fatigue severity scale
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Breathlessness1 study · 47 people took Specialized pro-resolving mediators (SPM Active) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 53 people found no clear difference; a small benefit can't be ruled out.
The randomised trial53 randomised · 12 weeks · 3000 mg/day
No clear difference in breathlessness.
The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on breathlessness in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 53 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Same trial, also reported in: Pro-resolving Inflammatory Effects of a Marine Oil Enriched in SPMs Supplement and Its Implication in Patients with a Post COVID Syndrome (PCS) (2024) (mMRC Dyspnea Scale score: differences among the four treatment groups)
- People in the study
- 53 randomised
- Dose
- 3000 mg/day
- Outcome
- mMRC Dyspnea Scale (baseline vs week 12 and week 4) Modified Medical Research Council (mMRC) Dyspnea Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Daily life and health overall
Daily functioning1 study · 144 people took Specialized pro-resolving mediators (SPM Active) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).
Studies with no comparison group144 randomised · after 12 weeks
Daily functioning improved.
The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on daily functioning in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 1 study
-
- People in the study
- 144 randomised
- Dose
- —
- Outcome
- functional capacity (6MWT) 6-minute walk test
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life1 study · 144 people took Specialized pro-resolving mediators (SPM Active) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group144 randomised · after 12 weeks
Quality of life improved.
The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on quality of life in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 144 randomised
- Dose
- —
- Outcome
- health-related quality of life (EQ‑5D‑5 L)
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 144 people took Specialized pro-resolving mediators (SPM Active) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 144 people found no clear difference; a small benefit can't be ruled out.
The placebo trial144 randomised · after 12 weeks
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of specialized pro-resolving mediators (SPM Active) on overall symptoms in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 144 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 144 randomised
- Dose
- —
- Outcome
- between-group differences
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
3000 mg at the start
- 2Top dose
Most often 3000 mg (2 of 2 studies)
Doses across 2 studies
3000 to 3000 mg.
Each study’s dose, as printed
- 3000 mg/day Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS). (2024)
- 3000 mg/day Pro-resolving Inflammatory Effects of a Marine Oil Enriched in SPMs Supplement and Its Implication in Patients with a Post COVID Syndrome (PCS) (2024)
All papers
- Effects of Specialized Pro-Resolving Mediators and Telerehabilitation on Fatigue, Dyspnea, and Quality of Life in Post‑COVID‑19 Condition: The ARACOV-02 Randomized Controlled Trial.2026 · placebo trial · 144 randomised · preprint
Summary
This triple-blind randomized controlled trial enrolled 144 people with Post-COVID-19 Condition (PCC). Participants were randomized 1:1 to receive either an SPM-enriched marine oil supplement or placebo; both groups also received a 12-week asynchronous telerehabilitation program delivered via the HEFORA platform. The primary outcome was health-related quality of life (EQ-5D-5L). Secondary outcomes included fatigue (FSS), dyspnea (mMRC), respiratory muscle strength (MIP/MEP), functional capacity (6MWT), and limb strength (30-s STST, 30-s ACT). Analyses followed an intention-to-treat approach. After 12 weeks, the trial found no statistically significant between-group differences (p > .05). Both groups showed significant within-group improvements. In the nutritional group, quality of life increased, fatigue decreased, and functional capacity improved (+ 37.82 m in 6MWT; p < .001); strength and respiratory pressures also increased significantly. Similar improvements were observed in the placebo group, except for dyspnea. Exploratory adherence-stratified analyses showed larger improvements among participants with higher adherence. Side effects were not reported in the available text. The authors state that the SPM-enriched supplement did not show superiority over placebo.
- Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS).2024 · randomised trial · 53 randomised
Summary
This randomized, double-blind, placebo-controlled trial with four parallel supplement groups assessed a food supplement enriched in specialized pro-resolving mediators in adults with Post-COVID Syndrome. The study was conducted in 53 adult patients with PCS, selected by their treating centers. Participants received daily doses of 3000 mg (group A, 16 patients), 1500 mg (group B, 16 patients), placebo (group C, 5 patients), or 500 mg (group X, 16 patients) for 12 weeks. Group X was an independent, non-controlled low-dose group and was not blinded. The Fatigue Severity Scale (FSS) and Modified Medical Research Council (mMRC) Dyspnea Scale were assessed at baseline and weeks 4 and 12. For FSS, no significant differences were detected among the four treatment groups; a clear trend in improvement was seen in group X (500 mg). An improvement of 9% in the mean fatigue value was observed between weeks 4 and 12 for patients on 500 mg daily. For mMRC, there were no significant differences in evolution among the four groups during the study (baseline vs week 12: X-squared = 8.2496, p = 0.509; baseline vs week 4: X-squared = 7.3615, p = 0.600). A slight improvement in mMRC was observed in all groups at the end of the study. Adverse events were collected; event counts and withdrawals for harms are not reported. Numbers who worsened or stopped are not reported. The authors state limitations including the small number of recruited patients and a natural trend of improvement in PCS symptoms.
- Pro-resolving Inflammatory Effects of a Marine Oil Enriched in SPMs Supplement and Its Implication in Patients with a Post COVID Syndrome (PCS)2024 · randomised trial · 53 randomised
Summary
This randomized, double-blind, placebo-controlled trial with four parallel supplement groups enrolled 53 adult patients with Post-COVID Syndrome (PCS) at three centers. Participants received a food supplement enriched in specialized pro-resolving mediators (SPMs) at 500 mg/day (Group X, N = 16), 1500 mg/day (Group B, N = 16), or 3000 mg/day (Group A, N = 16), or placebo (Group C, N = 5), daily for 12 weeks; the paper states group X was not blinded. Fatigue Severity Scale (FSS) scores and Modified Medical Research Council (mMRC) dyspnea scores were assessed from baseline to weeks 4 and 12. All groups tend to improve the fatigue symptoms included in the FSS questionnaire, and no significant differences are detected among the four treatment groups, but a clear trend in improvement can be seen in group X, which used 500 mg of marine oil per day. An improvement of 9% in the mean value for fatigue could be observed between weeks 4 and 12 for the patients on a dosage of 500 mg daily. For dyspnea, a slight improvement can be observed for each group regarding the frequency and percentage of patients in each grade of the scale, but there were no significant differences in the evolution of the mMRC scores among the four treatment groups during the study. The paper reports no adverse event counts, side-effect results, or withdrawals for harms in this study.
- Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.2024 · no comparison group · 852 in the study · 536 with outcome data
Summary
This cross-sectional follow-up survey asked patients with long COVID seen at a post-COVID clinic (PCoCC) about symptoms and treatments. A total of 852 patients were identified; 536 completed the survey. The mean time from COVID-19 infection to survey completion was 23.2 ± 6.4 months. There was no comparison group; patients rated symptoms at the initial clinic visit (baseline, by recall) and at follow-up on a 1-10 scale, and rated whether treatments were helpful. Surveyed treatments included low-dose naltrexone, vagal nerve stimulator, midodrine, fludrocortisone, pyridostigmine, aripiprazole, plasmapheresis, reishi mushroom and nattokinase/serrapeptase; treatment duration was not reported. Overall functioning median improved from 8 (6, 9) at baseline to 5 (3, 8) at follow-up (P < .001); fatigue improved from 8 (7,10) to 6 (3, 8) and brain fog from 8 (6, 9) to 5 (3, 8) (P < .001 for both). All individual symptoms assessed were significantly improved (P < .001). Only 4.5% (24/536) had recovered completely. Helpful ratings included low-dose naltrexone 45/77 (58%), vagal nerve stimulator 18/34 (53%), plasmapheresis 9/9 (100%), midodrine 7/17 (41%), fludrocortisone 8/17 (47%), pyridostigmine 2/3 (67%), aripiprazole 8/17 (47%), reishi mushroom 8/19 (42%) and nattokinase/serrapeptase 5/9 (56%). A minority worsened in overall function and in fatigue, myalgia and orthostasis; counts, side-effect counts, and withdrawals due to harms were not reported.